Mylan NV News - MYL

Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)

Table of Contents As filed with the Securities and Exchange Commission on May 6, 2022...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:September 28,

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Table of Contents Filed pursuant to Rule 424(b)(3) Registration Number 333-259463...

Securities Registration: Business Combination (s-4)

Table of Contents As filed with the Securities and Exchange Commission on September 10, 2021...

Termination of Registration of a Class of Security Under Section 13 and 15(d) (15-15d)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Current Report Filing (8-k)

false 0001623613 0001623613 2020-11-16 2020-11-16 UNITED STATES SECURITIES AND EXCHANGE...

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File...

Quarterly Report (10-q)

0001623613FALSE2020Q312/31P3Y00016236132020-01-012020-09-30xbrli:shares00016236132020-10-31iso4217:USDxbrli:...

Current Report Filing (8-k)

false000162361300016236132020-08-062020-08-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON...

Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc.

Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR...

Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris

Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Mylan NV (MYL)

Empower your portfolio: Real-time discussions and actionable trading ideas.

MYL News

Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)

Notice of Effectiveness (effect)

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Securities Registration: Business Combination (s-4)

Termination of Registration of a Class of Security Under Section 13 and 15(d) (15-15d)

Current Report Filing (8-k)

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...

Quarterly Report (10-q)

Current Report Filing (8-k)

Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc.

Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris

Pfizer, Mylan Agreement With FTC Over Upjohn Deal, Clearing Way for November Closing

Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL

MYL Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Mylan NV (MYL) News

Mylan NV (MYL)

Empower your portfolio: Real-time discussions and actionable trading ideas.

MYL News

Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)

Notice of Effectiveness (effect)

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Securities Registration: Business Combination (s-4)

Termination of Registration of a Class of Security Under Section 13 and 15(d) (15-15d)

Current Report Filing (8-k)

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...

Quarterly Report (10-q)

Current Report Filing (8-k)

Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc.

Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris

Pfizer, Mylan Agreement With FTC Over Upjohn Deal, Clearing Way for November Closing

Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn

Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL

MYL Discussion

Your Recent History